| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1153d3bb97cf3bed2c208616d50d42f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab5b1f4b4c2847403d9ff92f7eb7c5d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f1eec39b8522528f3a4e4229448c6a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53dfe966130ecffd9da6851ff3b7d88e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf08313740f94211770d9011a639ce9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33611e5a7b90e9a1b3d53c1d2a884d2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2014-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccc2950afe99a51cd371d13e8959d3ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_094393566d2b18ebed77498f25c51adf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7002b18563d964dcdfa4e1e0388c74fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dd7bf3a8d5646dadfa8a106ccbc2898
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dba02271449fc4c2ee75d9cc2721181
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e93de891848d8f0707a3e8ffd7caf0d0 |
| publicationDate |
2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015061367-A1 |
| titleOfInvention |
Genetic markers predictive of response to glatiramer acetate |
| abstract |
The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype corresponding to the nucleotide polymorphisms consisting of: Group 1, of the subject at a location location of one or more single (SNPs) selected from the group. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9625473-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9763993-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9155775-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9702007-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9499868-B2 |
| priorityDate |
2013-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |